Do non-clotting factor therapies actually reduce bleeding in congenital Hemophilia A?
Non-clotting factor therapies are designed to prevent bleeding episodes in people with Hemophilia A without replacing the missing clotting factor. Research shows these treatments lower the annualized bleeding rate and improve quality of life. A 2024 meta-analysis found that newer non-clotting factor therapies reduce bleeding in congenital hemophilia when compared to existing standards of care 1.
What the research says
A systematic review and meta-analysis evaluated gene therapy and non-clotting factor therapies against standard clotting factor prophylaxis. The study found that gene therapy reduced the annualized bleeding rate significantly compared to factor VIII prophylaxis. In addition, factor VIII use decreased by more than 96% in the fourth year of follow-up 2.
Specific trials for concizumab, an anti-tissue factor pathway inhibitor, confirmed its superiority over no prophylaxis. In the explorer7 study, the median annualized bleeding rate for patients receiving concizumab was 0.8 at 56 weeks. This is a marked reduction compared to patients receiving no prophylaxis 3.
These therapies also improve health-related quality of life. Patients treated with these agents experience fewer bleeding events and related complications. The evidence supports using these options to prevent bleeds in people with Hemophilia A or B 1.
What to ask your doctor
- How do non-clotting factor therapies compare to my current clotting factor prophylaxis in reducing bleeding?
- What are the side effects of concizumab or emicizumab for my specific case?
- Can I switch to a non-clotting factor therapy if I develop inhibitors to my clotting factors?
- How often do I need to take these medications to keep bleeding under control?
This question is drawn from common patient questions about Hematology and answered using cited medical research. We do not provide individualized advice.